-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis Pharma Reports 7.7% Placebo-Adjusted Weight Loss With Oral GLP-1 Drug ASC30 in Phase II Obesity Study

Reuters·12/08/2025 09:31:01

Please log in to view news